Aminocarbamoyl Compounds for Treatment of Viral Infections - Roche Patent
Summary
The European Patent Office published European Patent Application EP4204393A1, filed by F. Hoffmann-La Roche AG, covering aminocarbamoyl compounds for the treatment of viral infections. The patent application includes IPC classifications spanning organic chemistry compounds (C07C, C07D), peptide chemistry (C07K), and pharmaceutical preparations (A61K, A61P), designating 36 European contracting states.
What changed
The European Patent Office granted F. Hoffmann-La Roche AG European Patent Application EP4204393A1 for aminocarbamoyl compounds useful in treating viral infections. The patent covers multiple IPC classifications including C07K peptide chemistry (C07K5/062, C07K5/078), heterocyclic compounds (C07D series), and pharmaceutical compositions (A61K31/15, A61K31/27), designating 36 European contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
For pharmaceutical manufacturers and biotech companies, this patent represents a potential blocking position in the aminocarbamoyl compound space for antiviral therapeutics. Competitors developing similar compounds for viral infection treatment should conduct freedom-to-operate analyses and consider potential licensing arrangements with Roche to avoid infringement claims in designated European markets.
What to do next
- Monitor for updates
- Conduct freedom-to-operate analysis if developing similar compounds
- Review patent claims for licensing opportunities
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
Publication EP4204393A1 Kind: A1 Apr 01, 2026
Applicants
F. Hoffmann-La Roche AG
Inventors
CHEN, Jianguo, LIANG, Chungen, MIAO, Kun, WU, Yao, YUN, Hongying, ZHANG, Weixing
IPC Classifications
C07C 243/28 20060101AFI20260226BHEP C07C 271/22 20060101ALI20260226BHEP C07C 311/13 20060101ALI20260226BHEP C07D 207/26 20060101ALI20260226BHEP C07D 209/42 20060101ALI20260226BHEP C07D 211/76 20060101ALI20260226BHEP C07D 231/12 20060101ALI20260226BHEP C07D 233/64 20060101ALI20260226BHEP C07D 235/24 20060101ALI20260226BHEP C07D 261/18 20060101ALI20260226BHEP C07D 263/34 20060101ALI20260226BHEP C07D 403/12 20060101ALI20260226BHEP C07D 413/12 20060101ALI20260226BHEP C07D 471/04 20060101ALI20260226BHEP C07K 5/062 20060101ALI20260226BHEP C07K 5/078 20060101ALI20260226BHEP A61K 31/15 20060101ALI20260226BHEP A61K 31/27 20060101ALI20260226BHEP A61P 31/12 20060101ALI20260226BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.